109 related articles for article (PubMed ID: 22459446)
1. Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors.
Massimino KP; Han E; Pommier SJ; Pommier RF
Am J Surg; 2012 May; 203(5):628-631. PubMed ID: 22459446
[TBL] [Abstract][Full Text] [Related]
2. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
Wang SC; Parekh JR; Zuraek MB; Venook AP; Bergsland EK; Warren RS; Nakakura EK
Arch Surg; 2010 Mar; 145(3):276-80. PubMed ID: 20231629
[TBL] [Abstract][Full Text] [Related]
3. The role of wireless capsule endoscopy (WCE) in the detection of occult primary neuroendocrine tumors.
Furnari M; Buda A; Delconte G; Citterio D; Voiosu T; Ballardini G; Cavallaro F; Savarino E; Mazzaferro V; Meroni E
J Gastrointestin Liver Dis; 2017 Jun; 26(2):151-156. PubMed ID: 28617885
[TBL] [Abstract][Full Text] [Related]
4. Surgery for metastatic neuroendocrine tumors with occult primaries.
Bartlett EK; Roses RE; Gupta M; Shah PK; Shah KK; Zaheer S; Wachtel H; Kelz RR; Karakousis GC; Fraker DL
J Surg Res; 2013 Sep; 184(1):221-7. PubMed ID: 23643298
[TBL] [Abstract][Full Text] [Related]
5. Capsule endoscopy to detect primary tumour site in metastatic neuroendocrine tumours.
Frilling A; Smith G; Clift AK; Martin J
Dig Liver Dis; 2014 Nov; 46(11):1038-42. PubMed ID: 25086997
[TBL] [Abstract][Full Text] [Related]
6. Small bowel neuroendocrine tumors: A critical analysis of diagnostic work-up and operative approach.
Ethun CG; Postlewait LM; Baptiste GG; McInnis MR; Cardona K; Russell MC; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Nov; 114(6):671-676. PubMed ID: 27511436
[TBL] [Abstract][Full Text] [Related]
7. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable?
Wang YZ; Chauhan A; Rau J; Diebold AE; Opoku-Boateng A; Ramcharan T; Boudreaux JP; Woltering EA
Chin Clin Oncol; 2016 Feb; 5(1):4. PubMed ID: 26932428
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary - a plea for open exploration].
Begum N; Hubold C; Buchmann I; Thorns C; Bouchard R; Lubienski A; Schlöricke E; Zimmermann M; Lehnert H; Bruch HP; Bürk CG
Zentralbl Chir; 2014 Jun; 139(3):284-91. PubMed ID: 23508839
[TBL] [Abstract][Full Text] [Related]
10. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine liver metastases: contributions of endoscopy and surgery to primary tumor search.
Cerwenka H
World J Gastroenterol; 2012 Mar; 18(10):1009-14. PubMed ID: 22416174
[TBL] [Abstract][Full Text] [Related]
13. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
14. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy.
Miller FR; Karnad AB; Eng T; Hussey DH; Stan McGuff H; Otto RA
Head Neck; 2008 Jan; 30(1):28-34. PubMed ID: 17657782
[TBL] [Abstract][Full Text] [Related]
15. Management of neuroendocrine tumors of unknown primary.
Alexandraki K; Angelousi A; Boutzios G; Kyriakopoulos G; Rontogianni D; Kaltsas G
Rev Endocr Metab Disord; 2017 Dec; 18(4):423-431. PubMed ID: 29199361
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
Sergieva S; Robev B; Dimcheva M; Fakirova A; Hristoskova R
Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
[TBL] [Abstract][Full Text] [Related]
17. [The clinical characteristic of 43 cases of neuroendocrine tumors with liver metastases].
Li P; Yang XO; Qian JM
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):289-93. PubMed ID: 22781949
[TBL] [Abstract][Full Text] [Related]
18. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
19. (68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin.
Alonso O; Rodríguez-Taroco M; Savio E; Bentancourt C; Gambini JP; Engler H
Ann Nucl Med; 2014 Aug; 28(7):638-45. PubMed ID: 24862238
[TBL] [Abstract][Full Text] [Related]
20. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
